Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Delafloxacin

Phase 3Small molecule

MMelinta Therapeutics, Inc.

Delafloxacin is one of 73 small molecule programs targeting Gonorrhea. It is currently in Phase 3.

3

Indications

12

Total Trials

1

Active Trials

72

Competitors

Pipeline

Status by Indication[3][1]

Indication

GonorrheaActive, not recruiting

Bacterial PneumoniaActive, not recruiting

Skin InfectionActive, not recruiting

GonorrheaPhase 3

Active, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

Skin InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Bacterial Pneumonia

#DrugCompanyPhaseTrials

Teflaro

Biaxin

Ketek

Levaquin

Avelox

Zyvox

Avycaz

PPhiladelphia Eye Associates

Amikin

IInsmed Incorporated

Tygacil

PPrism Pharmaceuticals

Primaxin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Not yet recruiting

Bone and Joint Infection

NCT07426471

Clinical

Trials by Indication[1]

Skin Infection2 trials

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

Completed·MMelinta Therapeutics, Inc.·Phase 2·NCT01283581·256 enrolled

Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections

Completed·MMelinta Therapeutics, Inc.·Phase 2·NCT00719810·150 enrolled

Infections2 trials

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT01811732·660 enrolled

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT01984684·850 enrolled

Bacterial Pneumonia1 trial

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Completed·MMelinta Therapeutics, Inc.·Phase 3·NCT02679573·860 enrolled

Adult1 trial

A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults

Terminated·MMelinta Therapeutics, Inc.·Phase 1·NCT06612255·16 enrolled

Surgical Site Infections1 trial

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Terminated· Menarini logo

Menarini·Phase 3·NCT04042077·268 enrolled

5 more indications

Midazolam1 trial

Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects

Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT02505997·22 enrolled

Bone and Joint Infection1 trial

Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections.

Not yet recruiting·IIRCCS San Raffaele··NCT07426471·20 enrolled

Gonorrhea1 trial

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

Terminated·MMelinta Therapeutics, Inc.·Phase 3·NCT02015637·460 enrolled

Hepatic Impairment1 trial

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT02245243·40 enrolled

Intravenous1 trial

Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults

Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT03534622·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Delafloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Delafloxacin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Delafloxacin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Melinta Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMelinta Therapeutics, Inc.

Related News